We're seeing value health care ($XLV) show a lot of relative strength against other sectors as the dollar has been pushing. ($KRE) is often tied to growth when compared to it's bigger brother ($XLF) and eventhough financials do tend to benefit from rising rates, this has been much more of a hard landing and the financial rotation many expect may not come to pass,...
Teladoc Health, Inc. is a multinational telemedicine and virtual healthcare company headquartered in the United States. Trading at 72.9% below our estimate of its fair value Revenue is forecast to grow 18.84% per year
Technical Analysis : We broke the downtrend line and had three white soldiers to confirm the reversal of the trend, also the falling wedge shows a bullish reversal since we broke it upwards. Although on a lower timeframe MACD and RSI look bearish, we expect the price to reach our Buy Zone before the impulsive move upwards. Aroon : Aroon Up on Top and Aroon Down...
Downtrend Will Horizontal Price Movement within 1974-2101 can buy when drop near to support level . MYX:HEALTH
MYX:HEALTH Downtrend Will Horizontal Price Movement within 1974-2101 can buy when drop near to support level.
$ICLR may represent a buying opportunity on this pullback. Health care, specifically large cap health care like this one tend to do well in deflationary environments and with the Fed signaling 3 rate hikes in 2022 it may be an opportune time to get positioned.
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on October 29, 2021 at $15.70 per share. Our...
Looks like the MACD is still heading down but curling up. RSI is bottoming out as it reaches an important level of support. I think the risk reward at the $28 level is optimal. If you have a high risk tolerance, buy now. Shrooms are already decriminalized in Denver and are about to be in Detroit. The TAM which was initially an imaginative number is now becoming...
This recent $PFE spinoff who went public via SPAC in 2020 could be a strong portfolio holding in the months and years to come. Experienced leadership taking on the unique challenge of solving a lot of the mental health issues that could very well be leading to the tight labor markets we've witnessed recently.
ZNTL broke 80 again today and is displaying a strong monthly momentum chart. IBB regaining 160 hopefully will signal at least a moderate health care push that could push ZNTL into the 90s and beyond. Good luck traders!
In the last couple of months, $CLOV has seen a lot of volatility in the daily chart, current prices are close to support, and we could see a bounce to the 100 or 200 EMA if volume grows.
Investors should continue to watch Merck and how it plays out here at the 80 level as their COVID drug treatment is pending approval. I believe the market is absolutely sleeping on the significance of this drug and the kind of impact it will have. A treatment is an absolute game changer provided the politics of COVID do not disrupt innovation, transparency and...
Poor valuation on this company. It is not worth $3 billion market cap. Short put strategy naked put on technical indicators makes this a good investment. This stock will be going down.
Friday will be red in a few spots but also green in the medical area for this company. It is a play for you to make some options money on a #swingtrade
ALGN has been outpacing pretty much every major index on a monthly / weekly time frame. I expect this momentum to continue over the long run. Company has a significant economic moat and this could be turn into 1000+ quicker than you might think
XBI (Nasdaq biotech ETF) losing more key levels today and with other health care names already pretty saturated to the upside, could that mean CLOV isn't done falling?
Promising biotech setup here, had a nice break of 70 recently and may be looking to go higher. Potentially risky if XBI rolls over but strong momentum here nonetheless. Good luck traders!
*This is not financial advice, so trade at your own risks* *My team digs deep and finds stocks that are expected to perform well based off multiple confluences* *Experienced traders understand the uphill battle in timing the market, so instead my team focuses mainly on risk management* Recap: My team entered $MIRM on 5/28/21 at $16.30 per share. Today we're...